GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Avacta Group PLC (LSE:AVCT) » Definitions » Total Liabilities

Avacta Group (LSE:AVCT) Total Liabilities : £51.39 Mil (As of Dec. 2023)


View and export this data going back to 2003. Start your Free Trial

What is Avacta Group Total Liabilities?

Avacta Group's Total Liabilities for the quarter that ended in Dec. 2023 was £51.39 Mil.

Avacta Group's quarterly Total Liabilities declined from Dec. 2022 (£71.93 Mil) to Jun. 2023 (£65.01 Mil) and declined from Jun. 2023 (£65.01 Mil) to Dec. 2023 (£51.39 Mil).

Avacta Group's annual Total Liabilities increased from Dec. 2021 (£5.78 Mil) to Dec. 2022 (£71.93 Mil) but then declined from Dec. 2022 (£71.93 Mil) to Dec. 2023 (£51.39 Mil).


Avacta Group Total Liabilities Historical Data

The historical data trend for Avacta Group's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Avacta Group Total Liabilities Chart

Avacta Group Annual Data
Trend Jul13 Jul14 Jul15 Jul16 Jul17 Jul18 Dec20 Dec21 Dec22 Dec23
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.04 5.53 5.78 71.93 51.39

Avacta Group Semi-Annual Data
Jul13 Jan14 Jul14 Jan15 Jul15 Jan16 Jul16 Jan17 Jul17 Jan18 Jul18 Jan19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.78 9.48 71.93 65.01 51.39

Avacta Group Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Avacta Group's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=45.109+(5.954+0.323
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit)
+0+0)
=51.39

Total Liabilities=Total Assets (A: Dec. 2023 )-Total Equity (A: Dec. 2023 )
=73.191-21.805
=51.39

Avacta Group's Total Liabilities for the quarter that ended in Dec. 2023 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=45.109+(5.954+0.323
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit)
+0+0)
=51.39

Total Liabilities=Total Assets (Q: Dec. 2023 )-Total Equity (Q: Dec. 2023 )
=73.191-21.805
=51.39

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Avacta Group Total Liabilities Related Terms

Thank you for viewing the detailed overview of Avacta Group's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.


Avacta Group (LSE:AVCT) Business Description

Traded in Other Exchanges
Address
Unit 20, Ash Way, Thorp Arch Estate, West Yorkshire, Wetherby, GBR, LS23 7FA
Avacta Group PLC is a United Kingdom-based biotechnology company. The company offers its products through three segments that are Diagnostics, Therapeutics, and Animal Health. The company is developing novel cancer immunotherapies combining its two proprietary platforms Affimer biotherapeutics and precision tumor-targeted chemotherapy. The company operates in the United Kingdom, France, South Korea, Rest of Europe, Asia, and North America.

Avacta Group (LSE:AVCT) Headlines

No Headlines